LGD-4033 vs NA Semax Amidate
Moderate Research vs Well Studied
monitor Mechanism-based · 51% Both LGD-4033 and NA Semax Amidate can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
LGD-4033 NA Semax Amidate
Weight 338.25 Da 1,007.16 Da
Half-life ~24-36 hours 2-10 hours
Chain — 7 amino acids
Type Nonsteroidal selective androgen receptor modulator (C14H12F6N2O) Modified ACTH analog
Key Benefits
LGD-4033
01 Strongest SARM for lean muscle mass accrual, with clinical trial data supporting dose-dependent increases in lean body mass
02 Tissue-selective action with minimal stimulation of the prostate and other androgen-sensitive tissues
03 Clinical evidence of improved physical function (leg press strength, stair-climbing speed) in hip fracture patients
04 No aromatization to estrogen (no estrogen-related water retention or gynecomastia at the receptor level)
05 No conversion to DHT (reduced risk of androgenic hair loss and prostate stimulation compared to testosterone)
06 Convenient once-daily oral dosing due to 24-36 hour half-life
07 Phase 2 clinical data available, providing a stronger evidence base than most other SARMs
NA Semax Amidate
01 Direct brain access via olfactory nerves
02 Rapid onset (15-30 minutes)
03 Proven cognitive efficacy
04 Extended half-life vs standard Semax
05 Enhanced BDNF upregulation
Dosing Protocols
LGD-4033
5-10 mg/day / Once daily (oral)
NA Semax Amidate
600-1200mcg per administration / 1-2x daily for 10-30 days
Research protocol 200mcg 1x daily
Neuroprotection study 400mcg 1x daily
Side Effects
LGD-4033
Testosterone suppression (dose-dependent; more suppressive than Ostarine at equivalent doses, occurs in most users by week 4-6)
Water retention (non-estrogenic mechanism, typically mild to moderate, contributes to scale weight increase)
HDL cholesterol reduction (dose-dependent lipid impact observed in clinical trials)
Headaches (most common in the first 1-2 weeks, usually transient)
Fatigue or lethargy (related to testosterone suppression, typically becomes noticeable mid-cycle)
Reduced libido (related to HPG axis suppression, severity varies by dose and individual)
NA Semax Amidate
Mild nasal irritation (intranasal)
Slight headache initially
Contraindications
Pre-existing liver disease or elevated liver enzymes at baseline
Hormone-sensitive cancers (prostate cancer or other androgen-driven malignancies)
Pregnancy or potential pregnancy (teratogenic risk from androgen receptor agonism)
Breastfeeding
Age under 25 (incomplete endocrine system maturation and higher risk of HPG axis disruption)
Concurrent use of hepatotoxic medications without medical supervision
Known cardiovascular disease (insufficient long-term safety data for this population)
History of significant lipid abnormalities (LGD-4033 suppresses HDL)
Not recommended during pregnancy
Active nasal congestion or sinus infection
Individuals on neurotransmitter-affecting medications without consultation
Research Evidence
LGD-4033 NA Semax Amidate
Status Moderate Research Well Studied
References 5 studies 5 studies
Latest 2018 2025
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.